GlassScriptPhysician profile
Iman Essam Mohamed
NPI 1942297270
$4,278.30
in general payments reported to CMS, 2019-2025
16 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,964 · 2020: $39.42 · 2021: $11.92 · 2023: $1,800 · 2024: $117 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,665 · Food and Beverage: $566 · Education: $30.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,665.00 |
| Food and Beverage | $566.49 |
| Education | $30.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,703.97 | 2023-2025 | Imfinzi, Tagrisso, Calquence |
| Tosoh Bioscience, INC. | $1,632.00 | 2019 | |
| Tempus Ai, INC | $276.07 | 2025 | Xt Cdx |
| Medtronic USA, INC. | $162.30 | 2019 | |
| Genentech USA, INC. | $84.00 | 2019 | |
| Glaxosmithkline, LLC. | $81.80 | 2023-2024 | Jemperli, Zejula |
| Gilead Sciences, INC. | $81.68 | 2021-2024 | Trodelvy |
| Janssen Biotech, INC. | $75.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.34 | 2020-2025 | |
| Amgen INC. | $30.98 | 2023 | |
| Abbvie INC. | $24.53 | 2025 | |
| Merck Sharp & Dohme LLC | $23.00 | 2023 | Keytruda, Lynparza |
| Mirati Therapeutics, INC. | $22.34 | 2023 | Krazati |
| Dova Pharmaceuticals | $12.44 | 2020 | |
| Immunomedics, INC. | $11.66 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iman Mohamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.